Laidlaw and Company were recently smacked with an injunction in US Federal Court to discontinue the distribution of false and misleading materials relevant to the operations of Relmada Therapeutics. Laidlaw is the primary investment banker for Relmada and as such, that position mandates that Laidlaw adheres to their fiduciary responsibility to it. Both to Relmada […]
SOURCE: culturebytes.org at 11:42AM on December 19, 2016